Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599555 | 0.96 | KMT2A (0.75) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL20599882 | 0.95 | KMT2A (0.72) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL4544894 | 0.92 | KMT2A (0.68) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL20600116 | 0.92 | KMT2A (0.68) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29134934 | 0.84 | KMT2A (0.58) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL28598290 | 0.84 | ELANE (0.73) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL14510071 | 0.84 | KMT2A (0.58) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL10574401 | 0.84 | KMT2A (0.88) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL11823665 | 0.82 | KMT2A (0.83) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2535788 | 0.81 | KMT2A (0.81) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-117682973-A | Sulfonamide compound and medical application thereof | 中国药科大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-111344287-B | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-113861071-A | Synthetic method of aryl cyclobutane compound | 上海麦克林生化科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-111344287-A | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | KMT2A 2388/4885HTT 3458/4885SMN1; SMN2 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.